authors
- Socinski, M
- Creelan, B
- Horn, L
- Reck, M
- Paz-Ares, L
- Steins, M
- Felip, E
- van den Heuvel, M
- Ciuleanu, TE
- Badin, F
- Ready, N
- Hiltermann, TJN
- Nair, S
- Juergens, Rosalyn
- Peters, S
- Minenza, E
- Geese, WJ
- Bhagavatheeswaran, P
- Chen, A
- Carbone, DP
NSCLC, metastatic CheckMate 026: A phase 3 trial of nivolumab vs investigator's choice (IC) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage iv/recurrent programmed death ligand 1 (PD-L1)−positive NSCLC
Conferences
- Overview
- Research
- Identity
- Additional Document Info
- View All
Overview
status
publication date
- October 2016
has subject area
- 1112 Oncology and Carcinogenesis (FoR)
- Oncology & Carcinogenesis (Science Metrix)
published in
- Annals of Oncology Journal